Targeting dual cancer-specific antigens using novel immunotherapies with a safe and controlled immune booster for the treatment of advanced ovarian cancer

Panorama Research Incorporated received a $405,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period June 1, 2025 through May 31, 2027. The award supports research targeting dual cancer-specific antigens using novel immunotherapies with a safe and controlled immune booster for the treatment of advanced ovarian cancer. The project will be performed at the company's facility in Sunnyvale, California.

The award funds the development of advanced immunotherapy solutions leveraging Panorama Research's core expertise in antibody-based therapeutic development and preclinical research. The deliverables are anticipated to include novel immunotherapy candidates and supporting preclinical data demonstrating efficacy against ovarian cancer through dual-antigen targeting approaches. This research aligns with the DHA's mission to transform healthcare for military service members and the American public through innovative biomedical solutions addressing critical health challenges.